Synthroid and Opioids (Oxycodone, Hydrocodone, Tramadol) Interaction

At a glance

• Drug identity / levothyroxine sodium (brand Synthroid and others) is a thyroid hormone replacement; oxycodone, hydrocodone, and tramadol are opioid analgesics from different chemical subclasses
• Interaction type / pharmacokinetic (absorption-related), not a direct drug-drug binding or metabolic interaction
• Mechanism / opioid mu-receptor activation slows gastric emptying and intestinal transit, which is plausible but not directly proven to meaningfully reduce levothyroxine bioavailability in controlled studies of this specific pair
• Established comparator / other agents that slow or alter GI absorption (proton pump inhibitors, calcium, iron, some malabsorptive conditions) are well documented in the levothyroxine absorption literature; opioids are grouped with this category by extrapolation
• Tramadol-specific note / tramadol has serotonergic activity and a labeled seizure-threshold warning; untreated significant hypothyroidism is an independent seizure risk factor, so the combination warrants attention in poorly controlled hypothyroidism, though no established quantitative risk figure exists for this specific combination
• Monitoring / recheck TSH roughly 4-8 weeks after starting or materially changing chronic opioid therapy, consistent with general practice for any change that could affect levothyroxine absorption
• Not established / there is no verified randomized trial quantifying levothyroxine dose adjustment needs in opioid-treated patients; empirical dosing thresholds in this article reflect extrapolation and clinical judgment, not trial data

Can you take Synthroid with oxycodone, hydrocodone, or tramadol?

Yes. No regulatory label or major interaction database lists levothyroxine and opioid analgesics as contraindicated. The concern is pharmacokinetic rather than acute or dangerous: opioids can slow the gut in ways that plausibly interfere with how completely and how quickly levothyroxine is absorbed, particularly with regular, sustained opioid use rather than an occasional as-needed dose. The clinically relevant question for a patient already stable on levothyroxine is not whether the combination is allowed, but whether starting a scheduled opioid should prompt closer thyroid monitoring, and this article treats that as the operative question.

What is known versus what is plausible

Levothyroxine is a narrow-therapeutic-index drug whose absorption is known to be sensitive to gastric acidity, food, timing relative to other medications, and certain GI conditions. This is why the standard counseling for any levothyroxine product is to take it on an empty stomach, with water, and to separate it by 30 to 60 minutes from food, coffee, and other medications, and by several hours from calcium, iron, and antacids. That baseline instruction is well established and applies regardless of whether a patient also takes an opioid.

Opioids are well established to slow gastrointestinal motility through mu-opioid receptor activity in the myenteric plexus; this is the same mechanism responsible for opioid-induced constipation, a common and well-documented side effect of chronic opioid therapy. It is pharmacologically plausible that slower gastric emptying and intestinal transit could reduce or delay levothyroxine absorption in patients taking both drugs regularly.

What is not established is the magnitude of this effect for oxycodone, hydrocodone, or tramadol specifically. The original version of this article cited precise figures (an "18% higher dose requirement," a "1.4 mIU/L mean TSH increase," a "13.1% of patients needing dose increases") attributed to named studies. Those specific figures could not be verified against a located primary source and are not repeated here. Readers and clinicians should treat any such number as requiring verification against the current published literature rather than assuming it is established fact. The safest accurate statement is qualitative: chronic opioid use is a plausible, mechanistically coherent, but not rigorously quantified contributor to reduced levothyroxine absorption, grouped clinically with other GI-motility-altering drugs.

Oxycodone, hydrocodone, and tramadol: what differs between them

Oxycodone and hydrocodone share the same mu-receptor mechanism of GI slowing. Extended-release formulations (such as extended-release oxycodone or extended-release hydrocodone products) produce more sustained motility suppression across the day than immediate-release, short-acting doses, which is relevant if a patient takes both an extended-release opioid and levothyroxine in the morning. Combination products containing acetaminophen (for example, hydrocodone/acetaminophen) do not add an independent levothyroxine interaction; acetaminophen has no known pharmacokinetic interaction with levothyroxine.

Neither oxycodone nor hydrocodone is a substrate, inhibitor, or inducer of levothyroxine's metabolic pathway, and levothyroxine does not meaningfully affect oxycodone or hydrocodone metabolism. If an interaction exists, it operates through absorption timing and gut transit, not through hepatic enzyme competition.

Tramadol carries an additional consideration beyond shared GI effects. Tramadol has serotonergic and norepinephrine reuptake-inhibiting activity in addition to weak mu-agonism, and its FDA labeling carries warnings about lowered seizure threshold, particularly at higher doses or in patients with other seizure risk factors. Severe, poorly controlled hypothyroidism is separately recognized as a factor that can lower seizure threshold and alter neurologic status. This creates a plausible, additive concern in a patient whose hypothyroidism is significantly undertreated and who is also taking tramadol, but there is no established quantitative interaction risk specific to this combination, and tramadol is not contraindicated in adequately treated hypothyroidism. The practical implication is that hypothyroidism should be reasonably well controlled, and TSH should not be allowed to drift markedly upward, in a patient who needs tramadol for pain management.

The timing recommendation, and why it does not change with opioids

The counseling that matters most for this interaction is the one that already applies to levothyroxine generally: take it first thing in the morning, on an empty stomach, with water, and wait before eating or taking other medications. Extending that separation to a full hour before a morning opioid dose is a reasonable, low-cost precaution given the plausible mechanism, even though it has not been tested as a specific intervention in trials.

Evening or bedtime opioid dosing is a separate consideration. Because opioid-related gastroparesis is most active for hours after a dose, taking levothyroxine at bedtime alongside a nighttime opioid could plausibly leave the tablet in a slower-moving stomach for longer. Morning levothyroxine dosing, separated from any opioid dose, remains the more conservative approach for patients on around-the-clock opioid regimens.

Monitoring: what to check and when

Baseline TSH (and free T4 if already being followed) before starting a course of opioids expected to continue for more than a few weeks is reasonable practice, though this is a matter of clinical judgment rather than a formal labeled requirement specific to opioids. Rechecking TSH roughly 4 to 8 weeks after starting regular opioid therapy is consistent with the general principle, applied across many interacting drug classes, that thyroid function should be reassessed after a change that could plausibly affect levothyroxine absorption or requirement. The same logic applies in reverse: if a patient's levothyroxine dose was increased during opioid therapy and the opioid is later stopped or substantially reduced, TSH should be rechecked several weeks later to rule out iatrogenic over-replacement (suppressed TSH, symptoms of thyrotoxicosis) once normal gut motility returns.

If TSH has risen above a patient's individual target, an incremental levothyroxine dose increase, followed by a recheck, is standard practice for any cause of reduced absorption. The exact increment (commonly small, such as 12.5 to 25 mcg, titrated to response) is a matter of individualized clinical judgment and should be decided by the prescribing clinician based on the degree of TSH elevation, symptoms, and patient-specific factors such as cardiac history and age. This article does not provide individualized dosing instructions.

Severity classification across interaction databases

Commercial drug-interaction databases do not uniformly classify the levothyroxine-opioid interaction, and ratings can change as databases update their evidence review. Rather than repeat a specific rating that cannot be verified as current, clinicians and pharmacists should check the interaction classification in their institution's current Lexicomp, Micromedex, or equivalent decision-support tool at the time of prescribing (verify as of the date of use), since severity labels are volatile and vendor-specific.

What is consistent across sources is the character of the risk: this is described as a slow-developing, monitorable absorption issue rather than an acute or life-threatening interaction. No credible case reports of acute harm from combining levothyroxine with oxycodone, hydrocodone, or tramadol were located for this review. The realistic risk is a gradual return of hypothyroid symptoms over weeks in a previously well-controlled patient, not an emergency.

Alternative levothyroxine formulations

For patients whose TSH remains difficult to control despite correct timing and reasonable dose adjustment, liquid levothyroxine solutions and soft-gel capsule formulations are marketed on the premise that they depend less on gastric acidity and dissolution than standard tablets, which may make them less sensitive to some absorption-impairing conditions. This is a plausible and commonly cited rationale in the levothyroxine absorption literature, but the specific benefit in opioid-treated patients has not been demonstrated in a verified trial for this population, and any such switch should be considered only after timing optimization and standard dose adjustment have been tried, given the substantially higher out-of-pocket cost of brand soft-gel or liquid formulations compared with generic tablets.

Patient counseling points

Take levothyroxine first, on an empty stomach, with water only, and wait at least 30 to 60 minutes (a full hour is a reasonable extra margin) before taking an opioid with food.

If an opioid is taken in the evening, avoid also moving levothyroxine to bedtime; morning dosing separated from the opioid is preferable.

Report new or worsening fatigue, weight gain, cold intolerance, or constipation that seems out of proportion to the opioid itself. These symptoms can develop gradually over weeks and are easy to attribute incorrectly to the opioid or to the underlying pain condition.

Do not stop levothyroxine because an opioid was started, and do not stop an opioid because of a levothyroxine prescription. Make sure every prescriber involved, including any pharmacist filling both medications, knows about both drugs so that TSH monitoring is not missed.

Special populations

Post-thyroidectomy patients have no residual thyroid function to buffer absorption fluctuations and depend entirely on the exogenous dose. These patients may warrant closer monitoring intervals during opioid initiation, and for patients being treated to a suppressed TSH target for thyroid cancer risk stratification, any upward TSH drift deserves prompt attention rather than a routine wait-and-see approach.

Adults over 65 already have age-related reductions in gastric acid secretion that can independently reduce levothyroxine absorption, and they are also more sensitive to over-replacement, with atrial fibrillation and bone density risks associated with a chronically suppressed TSH. In this group, a clinician weighing whether to increase levothyroxine because of concurrent opioid therapy should balance the risk of under-treatment against the cardiac and skeletal risks of over-correction, and many clinicians accept a somewhat higher TSH target in older patients for this reason. This is a matter of guideline-informed clinical judgment rather than a fixed rule, and readers should not use this article to self-adjust a dose.

Evidence-boundary summary

Established: opioids slow GI motility through a mu-receptor mechanism; levothyroxine absorption depends on gastric and small-intestinal transit; standard levothyroxine counseling already requires separation from food and other drugs; tramadol carries a labeled seizure-threshold warning independent of thyroid status.

Plausible but not rigorously quantified for this drug pair: that chronic oxycodone, hydrocodone, or tramadol use meaningfully raises TSH or increases levothyroxine dose requirements in a defined percentage of patients; that soft-gel or liquid levothyroxine formulations specifically resolve opioid-related absorption problems.

Not established: any specific numeric TSH change, dose-increase percentage, or trial-based dose-titration algorithm for levothyroxine in opioid-treated patients. No randomized controlled trial testing levothyroxine dosing strategy specifically in opioid users was located for this review.

When to seek urgent care: new-onset seizure, severe confusion, chest pain, or signs of an opioid overdose (slowed or stopped breathing, unresponsiveness) require emergency evaluation and are not managed through thyroid dose adjustment.

Evidence-status interaction assessment

Questions this article can answer

Can I take Synthroid with oxycodone, hydrocodone, or tramadol? Yes, the combination is not contraindicated. Take levothyroxine on an empty stomach with water, separate it from the opioid dose by at least 30 to 60 minutes, and have TSH checked several weeks after starting regular opioid use.

Do opioids lower thyroid hormone levels directly? Opioids do not suppress the thyroid gland itself. The plausible mechanism is reduced absorption of the levothyroxine tablet due to slower GI transit, which can allow TSH to rise in a patient who depends on the medication for adequate hormone levels.

How long should I wait between levothyroxine and my opioid dose? At least 30 to 60 minutes is the standard levothyroxine separation window from food and other medications; extending to a full hour is a reasonable extra margin with an opioid given the plausible motility effect, though this specific interval has not been tested in a dedicated trial.

Does tramadol affect thyroid blood tests? Tramadol is not known to directly alter T3, T4, or TSH assays or thyroid hormone production. Its relevant caution is an independent, labeled seizure-threshold effect that is best managed by keeping hypothyroidism reasonably well controlled.

Do I need more levothyroxine if I start opioid pain medication? Possibly, but there is no established fixed rate or formula. The right approach is a TSH check several weeks after starting regular opioid therapy, with any dose change decided by the prescriber based on the result and the patient's individual clinical picture.

What symptoms suggest my thyroid medicine is not working because of an opioid? Increasing fatigue, unexplained weight gain, worsening constipation beyond what the opioid alone typically causes, cold intolerance, and mental sluggishness developing over several weeks after starting an opioid are reasons to have TSH rechecked.

A note on sources: several precise figures and quoted guideline language that appeared in an earlier draft of this article could not be verified against a located primary source and have been removed or converted into general, appropriately hedged statements. Clinicians and pharmacists using this page for practice decisions should confirm current FDA labeling for the specific levothyroxine and opioid products involved, current ATA hypothyroidism treatment guidance, and the current interaction rating in their institution's drug-interaction database, since dosing thresholds and severity classifications can change and are not reproduced here as fixed numbers.